Arzeda tells National Security Commission U.S. biotech lacks domestic manufacturing, risking commercial scale‑up to overseas partners

Arzeda, a Seattle enzyme-design startup that reaches about 1.8 billion consumers, says U.S. biotech companies have strong science but lack domestic manufacturing capacity and workforce, forcing them to rely on Western Europe and India; the National Security Commission on Emerging Biotechnology visited to hear calls for investment and infrastructure to keep production stateside.

SSana Biotechnology UUniversity of Washington